Ekso Bionics Reports First Quarter 2017 Results
May 09, 2017 20:10 pm UTC| Business
RICHMOND, Calif., May 09, 2017 -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), a robotic exoskeleton company, today reported financial results for the three months ended March 31, 2017. Recent Highlights and...
May 09, 2017 20:10 pm UTC| Business
MALVERN, Pa., May 09, 2017 -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biotechnology company, today announced that the U.S. Food and Drug Administration has accepted its New Drug Application (NDA)...
Ekso Bionics Reports First Quarter 2017 Results
May 09, 2017 20:10 pm UTC| Business
RICHMOND, Calif., May 09, 2017 -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), a robotic exoskeleton company, today reported financial results for the three months ended March 31, 2017. Recent Highlights and...
Ekso Bionics Reports First Quarter 2017 Results
May 09, 2017 20:10 pm UTC| Business
RICHMOND, Calif., May 09, 2017 -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), a robotic exoskeleton company, today reported financial results for the three months ended March 31, 2017. Recent Highlights and...
Ekso Bionics Reports First Quarter 2017 Results
May 09, 2017 20:10 pm UTC| Business
RICHMOND, Calif., May 09, 2017 -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), a robotic exoskeleton company, today reported financial results for the three months ended March 31, 2017. Recent Highlights and...
May 09, 2017 20:10 pm UTC| Business
MALVERN, Pa., May 09, 2017 -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biotechnology company, today announced that the U.S. Food and Drug Administration has accepted its New Drug Application (NDA)...
May 09, 2017 20:10 pm UTC| Business
MALVERN, Pa., May 09, 2017 -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biotechnology company, today announced that the U.S. Food and Drug Administration has accepted its New Drug Application (NDA)...